Seminars in Nuclear Medicine
Volume 38, Issue 1 , Pages 20-31 , January 2008

Radiopharmaceuticals for Renal Positron Emission Tomography Imaging

  • Zsolt Szabo, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Zsolt Szabo, MD, PhD, Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine, The Johns Hopkins Medical Institutions, 601 N Caroline St, Room # JHOC 3233, Baltimore, MD 21287.
    • ,
  • Jinsong Xia, MD, PhD
    • ,
  • William B. Mathews, PhD

References 

  1. Toronyi E, Hamar J, Magyar K, et al. Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion. Med Sci Monit. 2002;8:BR65–BR68
  2. Haller H, Maasch C, Dragun D, et al. Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease. Kidney Int. 1998;53:1550–1558
  3. Logan J, Fowler JS, Volkow ND, et al. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain. Nucl Med Biol. 2000;27:43–49
  4. Feinendegen LE, Herzog H, Wieler H, et al. Glucose transport and utilization in the human brain: Model using carbon-11 methylglucose and positron emission tomography. J Nucl Med. 1986;27:1867–1877
  5. Tian X, Chakrabarti A, Amirkhanov N, et al. Receptor-mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochem Soc Trans. 2007;35:72–76
  6. Tian X, Chakrabarti A, Amirkhanov NV, et al. External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras. Ann N Y Acad Sci. 2005;1059:106–144
  7. Redaelli CA, Tien YH, Kubulus D, et al. Hyperthermia preconditioning induces renal heat shock protein expression, improves cold ischemia tolerance, kidney graft function and survival in rats. Nephron. 2002;90:489–497
  8. Eckardt KU, Bernhardt WM, Weidemann A, et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl. 2005;S46–S51
  9. Blantz RC, Thomson SC, Peterson OW, et al. Physiologic adaptations of the tubuloglomerular feedback system [review]. Kidney Int. 1990;38:577–583
  10. Schnermann J, Briggs JP. Effect of angiotensin and other pressor agents on tubuloglomerular feedback responses. Kidney Int Suppl. 1990;30:S77–S80
  11. Cervenka L, Kramer HJ, Maly J, et al. Role of nNOS in regulation of renal function in angiotensin II-induced hypertension. Hypertension. 2001;38:280–285
  12. Braam B, Navar LG, Mitchell KD. Modulation of tubuloglomerular feedback by angiotensin II type 1 receptors during the development of Goldblatt hypertension. Hypertension. 1995;25:1232–1237
  13. Anderson WP, Kett MM, Stevenson KM, et al. Renovascular hypertension: Structural changes in the renal vasculature. Hypertension. 2000;36:648–652
  14. Denton KM, Anderson WP, Sinniah R. Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole. Am J Physiol Regul Integr Comp Physiol. 2000;279:R629–R638
  15. Denton KM, Fennessy PA, Alcorn D, et al. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol. 1992;262:F367–F372
  16. Simon M, Rockl W, Hornig C, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: Localization and [125I]VEGF binding sites. J Am Soc Nephrol. 1998;9:1032–1044
  17. Kanellis J, Paizis K, Cox AJ, et al. Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. Kidney Int. 2002;61:1696–1706
  18. Rini BI, Rathmell WK. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res. 2007;13:741s–746s
  19. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005;23:7889–7896
  20. Nagengast WB, de Vries EG, Hospers GA, et al. In Vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313–1319
  21. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48:2229–2239
  22. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med. 2006;47:2048–2056
  23. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457–10461
  24. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851–4856
  25. Ostendorf T, De Vriese AS, Floege J. Renal side effects of anti-VEGF therapy in man: A new test system. Nephrol Dial Transplant. 2007;22:2778–2780
  26. Otani A, Takagi H, Suzuma K, et al. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res. 1998;82:619–628
  27. Moravski CJ, Kelly DJ, Cooper ME, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension. 2000;36:1099–1104
  28. Collingridge DR, Carroll VA, Glaser M, et al. The development of [(124)I]iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002;62:5912–5919
  29. Cai W, Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci. 2007;12:4267–4279
  30. Choe YS, Lee KH. Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr Pharm Des. 2007;13:17–31
  31. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v) beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781–1785
  32. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70
  33. Chen X, Sievers E, Hou Y, et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271–279
  34. Yang DJ, Kim KD, Schechter NR, et al. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biother Radiopharm. 2002;17:233–245
  35. Lee KH, Song SH, Paik JY, et al. Specific endothelial binding and tumor uptake of radiolabeled angiostatin. Eur J Nucl Med Mol Imaging. 2003;30:1032–1037
  36. Shiue CY, Shiue GG, Alavi AA, et al. [18F]Fluoropropylsqualamine as an angiogenesis imaging agent. J Labelled Compounds Radiopharmaceuticals. 2001;44:S391–S392
  37. Mene P, Amore A. Apoptosis: potential role in renal diseases. Nephrol Dial Transplant. 1998;13:1936–1943
  38. Gobe GC, Harmon B, Leighton J, et al. Radiation-induced apoptosis and gene expression in neonatal kidney and testis with and without protein synthesis inhibition. Int J Radiat Biol. 1999;75:973–983
  39. Murakami Y, Takamatsu H, Taki J, et al. 18F-labelled annexin V: A PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging. 2004;31:469–474
  40. Keen HG, Dekker BA, Disley L, et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol. 2005;32:395–402
  41. Bauer C, Bauder-Wuest U, Mier W, et al. 131I-Labeled peptides as caspase substrates for apoptosis imaging. J Nucl Med. 2005;46:1066–1074
  42. Cauchon N, Langlois R, Rousseau JA, et al. PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging. 2007;34:247–258
  43. Aloya R, Shirvan A, Grimberg H, et al. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis. 2006;11:2089–2101
  44. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17:3458–3471
  45. Sasatomi Y, Sato H, Chiba Y, et al. Prognostic factors for renal amyloidosis: A clinicopathological study using cluster analysis. Intern Med. 2007;46:213–219
  46. Hawkins PN. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci. 1994;87:289–295(Lond)
  47. Schaffer J, Burchert W, Floege J, et al. Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients. Kidney Int. 2000;58:873–880
  48. Schaadt BK, Hendel HW, Gimsing P, et al. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med. 2003;44:177–183
  49. Wall JS, Kennel SJ, Paulus M, et al. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med. 2006;47:2016–2024
  50. Goethals P, Volkaert A, Vandewielle C, et al. 55Co-EDTA for renal imaging using positron emission tomography (PET): A feasibility study. Nucl Med Biol. 2000;27:77–81
  51. Yamashita M, Inaba T, Kawase Y, et al. Quantitative measurement of renal function using Ga-68-EDTA. Tohoku J Exp Med. 1988;155:207–208
  52. Greene MW, Tucker WD. An improved gallium-68 cow. Int J Appl Radiat Isot. 1961;12:62–63
  53. Ehrhardt GJ, Welch MJ. A new germanium-63/gallium-68 generator. J Nucl Med. 1978;19:925–929
  54. Schuhmacher J, Maier-Borst W, Wellman HN. Liver and kidney imaging with Ga-68-labeled dihydroxyanthraquinones. J Nucl Med. 1980;21:983–987
  55. Young H, Carnochan P, Zweit J, et al. Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur J Nucl Med. 1994;21:336–341
  56. Shelton ME, Green MA, Mathias CJ, et al. Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography. Circulation. 1990;82:990–997
  57. Nitzsche EU, Choi Y, Killion D, et al. Quantification and parametric imaging of renal cortical blood flow in vivo based on Patlak graphical analysis. Kidney Int. 1993;44:985–996
  58. Killion D, Nitzsche E, Choi Y, et al. Positron emission tomography: A new method for determination of renal function. J Urology. 1993;150:1064–1068
  59. Brooks DJ, Frackowiak RS, Lammertsma AA, et al. A comparison between regional cerebral blood flow measurements obtained in human subjects using 11C-methylalbumin microspheres, the C15O2 steady-state method, and positron emission tomography. Acta Neurol Scand. 1986;73:415–422
  60. Turton DR, Brady F, Pike VW, et al. Preparation of human serum [methyl-11C]methylalbumin microspheres and human serum [methyl-11C]methylalbumin for clinical use. Int J Appl Radiation and Isotopes. 1984;35:337–344
  61. Mintun MA, Ter Pogossian MM, Green MA, et al. Quantitative measurement of regional pulmonary blood flow with positron emission tomography. J Appl Physiol. 1986;60:317–326
  62. Hermansen F, Ashburner J, Spinks TJ, et al. Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan. J Nucl Med. 1998;39:1696–1702
  63. Kubo T, Kimori K, Nakamura F, et al. Blood flow and blood volume in the femoral heads of healthy adults according to age: measurement with positron emission tomography (PET). Ann Nucl Med. 2001;15:231–235
  64. Kihlberg T, Karimi F, Langstrom B. [(11)C] Carbon monoxide in selenium-mediated synthesis of (11)C-carbamoyl compounds. J Org Chem. 2002;67:3687–3692
  65. Hofman HA, Knaapen P, Boellaard R, et al. Measurement of left ventricular volumes and function with O-15-labeled carbon monoxide gated positron emission tomography: comparison with magnetic resonance imaging. J Nucl Cardiol. 2005;12:639–644
  66. Okazawa H, Yonekura Y, Fujibayashi Y, et al. Measurement of regional cerebral plasma pool and hematocrit with copper-62-labeled HSA-DTS. J Nucl Med. 1996;37:1080–1085
  67. Hoffend J, Mier W, Schuhmacher J, et al. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol. 2005;32:287–292
  68. Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med. 1995;36:1595–1601
  69. Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: A potential acetate analog for prostate tumor imaging—in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med. 2007;48:420–428
  70. Johnson HA. Diagnosis by the bit: A method for evaluating the diagnostic process. Ann Clin Lab Sci. 1989;19:323–331
  71. Szabo Z, Speth RC, Brown PR, et al. Use of positron emission tomography to study AT1 receptor regulation in vivo. J Am Soc Nephrol. 2001;12:1350–1358
  72. Owonikoko TK, Fabucci ME, Brown PR, et al. In vivo investigation of estrogen regulation of adrenal and renal angiotensin AT1 receptor expression by PET. J Nucl Med. 2003;45:94–100
  73. Weinberger MH, Fineberg NS, Fineberg SE, et al. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37:429–432
  74. Szabo Z, Mathews WB, Burns HD, Gibson RE, Kivlighn SD, Hamill TG, et al. Comparison of the pharmacological potency and AT1 receptor occupancy of the nonpeptide angiotensin antagonist E-3174. J Nucl Med. 1996;37:288P
  75. Kao PF, Szabo Z, Dannals RF, et al. Compartmental modeling of an angiotensin IP/AT1 receptor imaging agent: C-11 L-159,884. J Nucl Med. 1994;35:137P
  76. Kao PF, Szabo Z, Dannals RF, et al. Impulse response function of the angiotensin II/AT1 receptor imaging agent: Carbon-11 L-159,884. Eur J Nucl Med. 1994;21(suppl):774
  77. Kim SE, Scheffel U, Szabo Z, et al. In vivo labeling of angiotensin II receptors with a carbon-11-labeled selective nonpeptide antagonist. J Nucl Med. 1996;37:307–311
  78. Szabo Z, Sandberg K, Brown P, et al. Increased AT1 receptor expression after treatment with the ACE inhibitor lisinopril. J Nucl Med. 1999;40:92P–93P
  79. Szabo Z, Kao PF, Burns HD, et al. Investigation of angiotensin II/AT1 receptors with carbon-11-L-159,884: a selective AT1 antagonist. J Nucl Med. 1998;39:1209–1213
  80. Zober TG, Brown RP, Sandberg K, et al. PET demonstrates upregulation of the renal angiotensin-II (AT1) receptors in experimental renovascular hypertension. J Nucl Med. 2003;44:142P
  81. Szabo Z, Kao PF, Mathews WB, et al. Validation of the impulse response function of [C-11]L-159,884, an angiotensin II, AT1 selective tracer. J Nucl Med. 1996;37:288P
  82. Hong KW, Kim CD, Lee SH, et al. The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist. Fundam Clin Pharmacol. 1998;12:64–69
  83. Lee BH, Seo HW, Kwon KJ, et al. In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. J Cardiovasc Pharmacol. 1999;33:375–382
  84. Mathews WB, Yoo SE, Lee SH, et al. A novel radioligand for imaging the AT1 angiotensin receptor with PET. Nucl Med Biol. 2004;31:571–574
  85. Zober TG, Seckin E, Mathews WB, et al. Imaging the AT1 receptor with the radioligand [11C]KR31173 and PET in mice, dogs and baboons. Nucl Med Biol. 2006;33:5–13
  86. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11–34
  87. Unger T, Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc Res. 1994;28:146–158
  88. Hwang DR, Eckelman WC, Mathias CJ, et al. Positron-labeled angiotensin-converting enzyme (ACE) inhibitor: fluorine-18-fluorocaptopril (Probing the ACE activity in vivo by positron emission tomography). J Nucl Med. 1991;32:1730–1737
  89. Qing F, McCarthy TJ, Markham J, et al. Pulmonary angiotensin-converting enzyme (ACE) binding and inhibition in humans (A positron emission tomography study). Am J Respir Crit Care Med. 2000;161:2019–2025
  90. Matarrese M, Salimbeni A, Turolla EA, et al. 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. Bioorg Med Chem. 2004;12:603–611
  91. Naicker S, Bhoola KD. Endothelins: Vasoactive modulators of renal function in health and disease. Pharmacol Ther. 2001;90:61–88
  92. Khan MA, Dashwood MR, Mumtaz FH, et al. Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron. 1999;83:261–267
  93. Gibson RE, Fioravanti C, Francis B, et al. Radioiodinated endothelin-1: A radiotracer for imaging endothelin receptor distribution and occupancy. Nucl Med Biol. 1999;26:193–199
  94. Johnstrom P, Harris NG, Fryer TD, et al. (18)F-Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: Radiosynthesis and in vivo imaging using microPET. Clin Sci. 2002;103 Suppl 48:4S–8S(Lond)
  95. Ravert HT, Mathews WB, Hamill TG, et al. Radiosynthesis of a potent endothelin receptor antagonist. J Label Compounds Radiopharm. 2000;43:1205–1210
  96. Aleksic S, Szabo Z, Scheffel U, et al. In vivo labeling of endothelin receptors with [11C]L-753,037: Studies in mice and a dog. J Nucl Med. 2001;42:1274–1280
  97. Johnstrom P, Aigbirhio FI, Clark JC, et al. Syntheses of the first endothelin-A- and -B-selective radioligands for positron emission tomography. J Cardiovasc Pharmacol. 2000;36:S58–S60
  98. Johnstrom P, Rudd JH, Richards HK, et al. Imaging endothelin ET(B) receptors using [18F]-BQ3020: In vitro characterization and positron emission tomography (microPET). Exp Biol Med (Maywood). 2006;231:736–740
  99. Hoeltke C, Wagner S, Breyholz HJ, et al. Development, synthesis and in vitro evaluation of novel ET-A receptor PET-radioligands based on PD 156707. J Label Compds Radiopharm. 2007;50:S345
  100. Johnstrom P, Fryer TD, Richards HK, et al. In vivo imaging of cardiovascular endothelin receptors using the novel radiolabelled antagonist [18F]-SB209670 and positron emission tomography (microPET). J Cardiovasc Pharmacol. 2004;44:S34–S38
  101. Mathews WB, Zober TG, Ravert HT, et al. Synthesis and in vivo evaluation of a PET radioligand for imaging the endothelin-A receptor. Nucl Med Biol. 2006;33:15–19

 The research related to this publication has been supported by NIH grants DK-50,183 and CA-115532 and by a grant from the Center for Biological Modulators/KRICT Korea.

PII: S0001-2998(07)00114-6

doi: 10.1053/j.semnuclmed.2007.09.008

Seminars in Nuclear Medicine
Volume 38, Issue 1 , Pages 20-31 , January 2008

Article Tools

* Image Usage & Resolution